Dennis P M Hughes1. 1. The Children's Cancer Hospital at MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 853, Houston, TX 77030, USA. dphughes@mdanderson.org
Abstract
BACKGROUND: Conventional therapy for osteosarcoma has reached a plateau of 60 - 70%, a 5-year survival rate that has changed little in two decades, highlighting the need for new approaches. OBJECTIVE: To review the alternative means of delivering effective therapy for osteosarcoma that reach beyond the central venous catheter. METHODS: Drawing on the author's own experiences providing care to high-risk osteosarcoma patients and reviewing the last two decades of literature describing sarcoma therapy, available information is summarized about potential osteosarcoma treatments that deliver therapy by a less conventional route. RESULTS/ CONCLUSIONS: Intra-arterial chemotherapy has a limited impact on survival, but may help to achieve a better limb salvage. Intrapleural chemotherapy is important for managing malignant effusions. The development of inhalation therapies, treatments that target new bone formation such as bisphosphonates, chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy.
BACKGROUND: Conventional therapy for osteosarcoma has reached a plateau of 60 - 70%, a 5-year survival rate that has changed little in two decades, highlighting the need for new approaches. OBJECTIVE: To review the alternative means of delivering effective therapy for osteosarcoma that reach beyond the central venous catheter. METHODS: Drawing on the author's own experiences providing care to high-risk osteosarcomapatients and reviewing the last two decades of literature describing sarcoma therapy, available information is summarized about potential osteosarcoma treatments that deliver therapy by a less conventional route. RESULTS/ CONCLUSIONS: Intra-arterial chemotherapy has a limited impact on survival, but may help to achieve a better limb salvage. Intrapleural chemotherapy is important for managing malignant effusions. The development of inhalation therapies, treatments that target new bone formation such as bisphosphonates, chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy.
Authors: Nancy Gordon; Nadezhda V Koshkina; Shu-Fang Jia; Chand Khanna; Arnulfo Mendoza; Laura L Worth; Eugenie S Kleinerman Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: J C Lattimer; L A Corwin; J Stapleton; W A Volkert; G J Ehrhardt; A R Ketring; S K Anderson; J Simon; W F Goeckeler Journal: J Nucl Med Date: 1990-08 Impact factor: 10.057
Authors: Peter M Anderson; Gregory A Wiseman; Angela Dispenzieri; Carola A S Arndt; Lynn C Hartmann; William A Smithson; Brian P Mullan; Oyvind S Bruland Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Ram Mohan Ram Kumar; Matthias Je Arlt; Aleksandar Kuzmanov; Walter Born; Bruno Fuchs Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166
Authors: Patrice Penfornis; David Z Cai; Michael R Harris; Ryan Walker; David Licini; Joseph D A Fernandes; Griffin Orr; Tejaswi Koganti; Chindo Hicks; Spandana Induru; Mark S Meyer; Rama Khokha; Jennifer Barr; Radhika R Pochampally Journal: Cancer Med Date: 2014-05-07 Impact factor: 4.452